🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

" TREX1 Gene Mutations and Their Role in Systemic Lupus Erythematosus

Recruitingn/aAges 18 Years - 60 YearsAllSouth Valley University
NCT07397728 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Systemic lupus erythematosus (SLE) is a multisystem autoimmune disease characterized by diverse clinical manifestations, prominently involving the skin.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Adult aged 18-60 years * Diagnosed as SLE per 2019 EULAR/ACR classification criteria. * Presence of at least one cutaneous manifestation (acute, subacute, or chronic). * Willing to provide written informed consent for participation and genetic testing Exclusion Criteria: * Overlap autoimmune syndromes (e.g., dermatomyositis, systemic sclerosis). * Systemic infection, malignancy, or pregnancy. * Use of biologic therapy or immunosuppressive pulses within one month.
💊

What it tests

  • TREX1 gene polymorphisms
📍

Where

1 site
Qina University hospital, South Valley University Hospital
Qina, Egypt
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy